|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/436 | |
| A61K 31/519 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Number of the document | 2558092 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11715370.0 |
| Date of filing the European patent application | 2011-04-12 | |
| (97) | Date of publication of the European application | 2013-02-20 |
| (45) | Date of publication and mention of the grant of the patent | 2018-06-27 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/032062 |
| Date | 2011-04-12 |
| (87) | Number | WO 2011/130232 |
| Date | 2011-10-20 |
| (30) | Number | Date | Country code |
| 323541 P | 2010-04-13 | US |
| (72) |
BORLAND, Maria, US
BRAIN, Christopher Thomas, US
DOSHI, Shivang, US
KIM, Sunkyu, US
MA, Jianguo, US
MURTIE, Josh, US
ZHANG, Hong, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE 6 (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER |
| COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE 6 (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER |